Answers are grounded in this paper and cite their sources.
Parkinson's disease (PD) is defined by nigrostriatal dopaminergic loss and α-synuclein (α-syn) pathology, yet constipation and rapid eye movement sleep behaviour disorder frequently precede motor onset by years, suggesting that pathology may originate in the gut. This review synthesises current evidence on the microbiota–gut–brain axis in PD along a single chain: dysbiosis, intestinal barrier failure and enteric neuroinflammation, α-syn misfolding, ascending spread via vagal and haematogenous routes, microglia-driven neuroinflammation and dopaminergic degeneration, with brain-to-gut feedback and dopaminergic medication closing a self-reinforcing loop. Each pathway is graded with a dual-track evidence score, reported separately for preclinical and human studies, which makes the central weakness of the field explicit rather than averaged away. The largest gaps occur for faecal microbiota transplantation (preclinical 9 versus human 2) and incretin-based disease-modifying therapy (9 versus 3), whereas microbial metabolism of levodopa is the only mechanistic pathway in which human evidence (10) exceeds preclinical evidence (9) and is therefore immediately actionable in clinical practice. We further argue that the negative phase III result for exenatide reflects a design deficit rather than a mechanistic one: cohorts were not stratified by gut-first phenotype, endpoints were insensitive to axis-specific benefit, and intervention began after substantial neuronal loss. Seed amplification assays, although diagnostically strong, are matrix- and stage-dependent, and should not be presented as validated population screening tools. The intestinal virome and mycobiome remain an unweighted evidence layer whose conclusions cannot be extrapolated from bacterial data. We conclude that the gut–brain axis in PD has moved from hypothesis to testable mechanism, but not yet to causally established, standard-of-care therapy; the priority requirements are axis-specific clinical endpoints, treatment-naive prospective cohorts, enteric-brain organoid platforms, and stratified trial designs.
No takes yet. Share an insight, caveat, or question.
Zewei Wang (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: